Emerging treatments for hepatitis C

Bibliography

• Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl2):1-3
   PubMed Web of Science ®Google Scholar
• Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl2):30-60
   PubMed Web of Science ®Google Scholar
• Spahn CM, Kieft JS, Grassucci RA, et al. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit. Science 2001;291:1959-62
   PubMed Web of Science ®Google Scholar
• EASL–EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
   PubMed Web of Science ®Google Scholar
• Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open 2012;2:e001313
   Google Scholar
• Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma. Ann Intern Med 2013;158:329-37
   PubMed Web of Science ®Google Scholar
• Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishi K, Aizaki H, Wakata T. Hepatitis C viral life cycle. Adv Drug Deliv Rev 2007;59:1200-12
   PubMed Web of Science ®Google Scholar
• Bruno S, Crosignani A, Maiaonneuve P, et al. Hepatitis C virus genotype 1b as a major risc factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007;46:1350-6
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
   PubMed Web of Science ®Google Scholar
• Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004;39:5-19
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56(S1):S88-100
   PubMedGoogle Scholar
• Flisiak R, Parfieniuk-Kowerda A. Cyclophilin inhibitors. Curr Hepat Rep 2012;11:153-9
   Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme. J Hepatol 2013; In press
   Google Scholar
• Craxì A, Pawlotsky JM, Wedemeyer H, et al. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895-903
   PubMed Web of Science ®Google Scholar
• Desai A, Reau N. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis 2011;15:483-95
   PubMed Web of Science ®Google Scholar
• Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C Virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-70
   PubMed Web of Science ®Google Scholar
• Maratea D, Messori A, Fadda V. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis. Dig Liver Dis 2012;44:86-7
   PubMedGoogle Scholar
• Deuffic-Burban S, Mathurin P, Pol S, et al. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut 2012;61:290-6
   PubMed Web of Science ®Google Scholar
• Turner SJ, Brown J, Paladino JA. Protease inhibitors for hepatitis C: economic implications. Pharmacoeconomics 2013;31(9):739-51
   PubMed Web of Science ®Google Scholar
• Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm 2013;19:438-47
   PubMed Web of Science ®Google Scholar
• Fontaine H, Hézode C, Dorival C, et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). J Hepatol 2013;58(S1):S27
   Google Scholar
• Berg T, Buggisch P, Hueppe D, et al. Real-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C Gt1 in Germany – an interim analysis. J Hepatol 2013;58(S1):S324
   Google Scholar
• Christensen S, Mauss S, Eisenbach C, et al. Week 4 and 12 efficacy of telaprevir (TVR) in combination with peginterferon alfa 2a/ribavirin (P/R) in treatment experienced patients with GT-1 under real life conditions. J Hepatol 2013;58(S1):S329
   PubMedGoogle Scholar
• Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013;8:e55285
   PubMed Web of Science ®Google Scholar
• Maasoumy B, Port K, Markova AA, et al. Triple therapy for hepatitis C virus (HCV) infection in patients with compensated liver cirrhosis: lessons learned from the first real-world experience. J Hepatol 2013;58(S1):S351
   Google Scholar
• Mauss S, Eisenbach C, Moeller B, et al. Substantial renal impairment is not infrequent in HCV patients under triple therapy with telaprevir or boceprevir. J Hepatol 2013;58(S1):S358
   PubMedGoogle Scholar
• Kapelusznik L, Majid AM, Cox ER, et al. Boceprevir is associated with decline in renal function in a cohort of HCV-treated patients. J Hepatol 2013;58(S1):S342
   PubMedGoogle Scholar
• Brooks LH Jr, Schwebke K, Livornese R, et al. Low treatment rates and suboptimal treatment completion rates to hepatitis C virus (HCV) therapy: a real-world analysis of a large US cohort. J Hepatol 2013;58(S1):S363
   Google Scholar
• Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; doi: 10.1002/hep.26641
   Google Scholar
• Manns M, Marcellin P, Poordad FF, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 2013;58(S1):S568
   Google Scholar
• Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVERSO1, a randomised, double-blind, placebo-controlled phase III trial. J Hepatol 2013;58(S1):S569-S70
   Google Scholar
• Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Manns MP, Gane E, Rodriguez-Torres M, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study. Hepatology 2012;56:884-93
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol 2013;59:11-17
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100-7
   PubMed Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
   PubMed Web of Science ®Google Scholar
• Lawitz E, Wyles D, Davis MN, et al. Sofosbuvir + peginterferon + ribavirin for 12 weeks achieves 90% SVR12 in genotype 1, 4, 5, or 6 hcv infected patients: the NEUTRINO study. J Hepatol 2013;58(S1):S567
   Google Scholar
• Kulkarni R, Ackrill AM, Moreira S, et al. Predictors of sustained virologic response (SVR) and relapse in patients with chronic hepatitis C infection who achieved an early rapid virologic response (eRVR) with mericitabine (MCB) plus peginterferon alfa-2a (40KD)/ribavirin (P/R). Hepatology 2012;56(S1):585A
   PubMedGoogle Scholar
• Wedemeyer H, Jensen D, Herring R. Jr, et al. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 2013; [Epub ahead of print]
   PubMedGoogle Scholar
• Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013;59:375-82
   PubMed Web of Science ®Google Scholar
• Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12:671-7
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24
   PubMed Web of Science ®Google Scholar
• Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012;56(S1):553A
   Google Scholar
• Thompson AJ, Shiffman ML, Rossaro L, et al. Six weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR4 rates in genotype 1 IL28B CC treatment naïve HCV patients: interim results of a prospective, randomized trial. Hepatology 2012;56(S1):556A
   Google Scholar
• Marcellin P, Manns M, Janczewska Kazek E, et al. 12 week response-guided treatment with the NS5A inhibitor, GS-5885, the NS3 protease inhibitor, GS-9451, plus pegylated interferon/ribavirin in treatment naive genotype 1 hepatitis c infected patients. J Hepatol 2013;58(S1):S355
   Google Scholar
• Griffel L, Bao W, Orsenigo R, et al. Interferon (IFN)-free alisporivir (ALV) has a better overall safety profile compared to IFN-containing treatment: a pooled analysis of the ALV development program. J Hepatol 2013;58(S1):S336-7
   Google Scholar
• Flisiak R, Pawlotsky JM, Crabbe R, et al. Once daily alisporivir (DEB025) plus pegifnalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients. J Hepatol 2011;54(S1):S2
   Google Scholar
• Buti M, Flisiak R, Rasenack J, et al. Alisporivir (ALV) plus peginterferon/ribavirin (PR) achieves high SVR12 rates among null responders, IL28BCT/TT and cirrhotic HCVG1 patients (FUNDAMENTAL study interim analysis). J Hepatol 2013;58(S1):S572
   Google Scholar
• Wedemeyer H, Janczewska Kazek E, Wlodzimierz M, et al. Phase II HCVac study of TG4040 immunotherapeutic in combination with pegifna2a and ribavirin in genotype 1 CHC treatment naive patients: SVR24 final results. J Hepatol 2013;58(S1):S28
   Google Scholar
• Schiffman ML, Muir A, Vierling J, et al. GI-5005 Therapeutic vaccine enhances virologic clearance by peg-ifn/ribavirin in naive HCV genotype 1 patients with IL28B genotype T/T. Hepatology 2012;56(S1):570A-1A
   Google Scholar
• Fredlund P, Hillson JL, Gray TE, et al. Peginterferon Lambda-1a (Lambda) is associated with less autoimmune thyroid disease and serious autoimmune disease than peginterferon alfa-2a (alfa) when used in combination with ribavirin (RBV) for the treatment of chronic hepatitis c virus infection. Hepatology 2012;56(S1):571A
   Google Scholar
• Vierling JM, LaTaillade M, Gane EJ, et al. Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study. Hepatology 2012;56:1522A-3A
   Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9
   PubMed Web of Science ®Google Scholar
• Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13:5673-81
   PubMed Web of Science ®Google Scholar
• Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
   PubMed Web of Science ®Google Scholar
• Gane E, Stedman CA, Hyland RH, et al. All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the Electron study. J Hepatol 2013;58(S1):S6-7
   Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. J Hepatol 2013;58(S1):S2
   Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naïve patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. Hepatology 2012;56:1517A-8A
   Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV GT 1, 2, or 3. Hepatology 2012;56:1516A-7A
   Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol 2013;58(S1):S570-80
   Google Scholar
• Lok AS, Gardiner DF, Hezode C, et al. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Hepatology 2012;56(S1):230A-1A
   Google Scholar
• Feld J, Jacobson IM, Jensen D, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) ± peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Hepatology 2012;56(S1):231A-2A
   Google Scholar
• Gane E, Lawitz E, Rodriguez-Torres M, et al. Phase 3 randomized controlled trial of all-oral treatment with sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of PEG + ribavirin in treatment-naïve GT 2/3 HCV-infected patients (FISSION). J Hepatol 2013;58(S1):S3
   Google Scholar
• Nelson D, Feld J, Kowdley K, et al. All oral therapy with sofosbuvir + ribavirin for 12 or 16 weeks in treatment experienced genotype 2/3 HCV-infected patients: results of the phase 3 FUSION trial. J Hepatol 2013;58(S1):S3-4
   Google Scholar
• Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009;49:1460-8
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Flisiak I, Lapinski T. Update on alisporivir in treatment of viral hepatitis C. Expert Opin Investig Drugs 2012;21:375-82
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Sarin SK, Foster GR, et al. Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study. Hepatology 2012;56(S1):309A
   Google Scholar
• Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther 2013;38:124-33
   PubMed Web of Science ®Google Scholar
• De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 2012;56:2106-15
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24
   PubMed Web of Science ®Google Scholar
• Mauss S, Boeker KHW, Eisenbach C, et al. Real-world efficacy and safety of telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis from the german non-interventional PAN study. J Hepatol 2013;58:S357-8
   Web of Science ®Google Scholar
• Moog G, Schober A, Antoni C, et al. Real-world efficacy and safety of boceprevir in combination with peginterferon alfa-2a and ribavirin in treatment-naive patients: interim analysis from the German non-interventional pan study. J Hepatol 2013;58(S1):S359-60
   Google Scholar
• Spengler U, Schober A, John C, et al. Real-world efficacy of boceprevir in combination with peginterferon alfa-2a and ribavirin in treatment-experienced patients: interim analysis from the German non-interventional PAN study. J Hepatol 2013;58(S1):S374
   Google Scholar
• Janczewska E, Flisiak R, Berak H, et al. Ribavirin dose reduction during telaprevir containing triple therapy does not affect early virologic response in non-responders and relapsers with advanced liver fibrosis. J Hepatol 2013;58(S1):S334-5
   Google Scholar
• Fried MW, Reddy KR, Di Bisceglie A, et al. HCV-TARGET: a longitudinal, observational study of North American patients with chronic hepatitis c (HCV) treated with boceprevir or telaprevir. J Hepatol 2013;58(S1):S335
   PubMedGoogle Scholar
• Colombo M, Fernandez I, Abdurakhmanov D, et al. Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the international telaprevir early access program. Hepatology 2012;56:1526A-7A
   Web of Science ®Google Scholar
• Calleja JL, Pascasio JM, Ruiz-Antoran B, et al. Efficacy and safety of triple-therapy with peginterferon-ribavirin, and boceprevir as compassionate-use in Spanish patients with hepatitis C genotype 1 with severe fibrosis: interim-analysis at 12 weeks. J Hepatol 2013;58(S1):S326-7
   Google Scholar